Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 4, 2025
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially
AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially
Read more at globenewswire.comNASDAQ:AXSM (8/19/2025, 11:55:58 AM)
110.94
-0.19 (-0.17%)
Find more stocks in the Stock Screener
AXSM Latest News and Analysis
